UNSPSC 51385903: Apazone or azapropazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2VOT966ZI, chemically known as 1,2-dihydro-3-dimethylamino-7-methyl-1,2-(propylmalonyl)-1,2,4-benzotriazine but generally known as apazone, which bears US NIH Compound Identifier 26098. Apazone most often comes in base and dihydrate forms. European Medicines Agency schedules Azapropazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05638MIG.

UNSPSC 51385903 Apazone or azapropazone is a Commodity code that in practice covers pharmaceutical products and medical supplies procured by state and local health agencies, though recent state and local opportunities tagged to this code show minimal direct activity for the specific chemical compound and instead reflect broader pharmaceutical procurement across naloxone, generic pharmaceuticals, and OTC products. State and local buyers under this code mix typically include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida (an IFB posted June 30, 2026) and the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (an RFP posted January 20, 2026) represent the issuing-body types active in this space, with the latter serving participating state and local government facilities across multiple states including Oregon.

Recent activity concentrates in Florida and Minnesota. Seminole County's IFB (due July 26, 2023) seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to Sanford, Florida, requiring vendors to include all shipping and delivery costs and meet E-Verify and drug-free workplace compliance. The Minnesota Multistate Cooperative Purchasing Alliance RFP (due March 26, 2026) establishes multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers—AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson—with awarded vendors effective July 1, 2026, pricing weighted 75 percent on competitiveness and compliance with cGMP and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission also posted an RFI (April 3, 2026) exploring direct-to-manufacturer prescription programs, signaling emerging state interest in alternative pharmaceutical distribution models outside traditional PBM and GPO channels.